A US based biopharmaceutical company Cephlon Inc has filed a suit against an Indian drug manufacturer company Glenmark Pharmaceuticals. The suit is a result of patent infringement by Glenmark.
Cephlon Inc has filed a patent infringement suit on 26 December 2013 in the US District Court. Glenmark has plans to sell generic version of leukaemia treatment drug in the American market before the expiry of patent.
Cephlon Inc seeks to prevent Glenmark from commercializing its Abbreviated New Drug Application (ANDA) for Bendamustine Hydrochloride product. Bendamustine is a generic version of Treanda.
Bendamustine is indicated for the treatment of patients with chronic lymphocytic leukemia
Leukaemia is a type of cancer of the blood or bone marrow characterized by an abnormal increase of immature white blood cells called "blasts". Leukemia is a broad term covering a spectrum of diseases. In turn, it is part of the even broader group of diseases affecting the blood, bone marrow, and lymphoid system.
Leukemia is a treatable disease. Most treatments involve chemotherapy, medical radiation therapy, hormone treatments, or bone marrow transplant.
If you have any Question/Point on the above information, please ask/discuss it in the Current Affairs Group
DISCLAIMER: JPL and its affiliates shall have no liability for any views, thoughts and comments expressed on this article.